Equities analysts expect ImmunoGen, Inc. (NASDAQ:IMGN) to report earnings of ($0.30) per share for the current quarter, according to Zacks Investment Research. Four analysts have made estimates for ImmunoGen’s earnings. The lowest EPS estimate is ($0.48) and the highest is ($0.13). ImmunoGen posted earnings per share of ($0.46) during the same quarter last year, which would suggest a positive year over year growth rate of 34.8%. The company is expected to issue its next earnings results on Friday, October 27th.

On average, analysts expect that ImmunoGen will report full-year earnings of ($0.85) per share for the current year, with EPS estimates ranging from ($0.94) to ($0.78). For the next year, analysts expect that the business will post earnings of ($1.44) per share, with EPS estimates ranging from ($1.64) to ($0.98). Zacks Investment Research’s EPS calculations are an average based on a survey of research analysts that follow ImmunoGen.

ImmunoGen (NASDAQ:IMGN) last released its earnings results on Friday, July 28th. The biotechnology company reported ($0.10) EPS for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.07. The business had revenue of $39.02 million during the quarter, compared to analyst estimates of $30.59 million. During the same period last year, the business posted ($0.53) EPS. ImmunoGen’s revenue was up 426.6% compared to the same quarter last year.

IMGN has been the subject of several research reports. Leerink Swann reaffirmed a “buy” rating on shares of ImmunoGen in a research note on Tuesday. BidaskClub raised ImmunoGen from a “hold” rating to a “buy” rating in a report on Saturday, August 26th. Cowen and Company reaffirmed a “hold” rating on shares of ImmunoGen in a report on Saturday, May 6th. Canaccord Genuity set a $8.00 target price on ImmunoGen and gave the company a “buy” rating in a report on Monday, July 31st. Finally, Royal Bank Of Canada raised ImmunoGen from a “sector perform” rating to an “outperform” rating and upped their target price for the company from $5.00 to $12.00 in a report on Thursday, July 6th. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $8.01.

ILLEGAL ACTIVITY WARNING: This piece of content was reported by American Banking News and is the property of of American Banking News. If you are accessing this piece of content on another site, it was illegally stolen and republished in violation of US and international copyright & trademark legislation. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2017/08/31/0-30-earnings-per-share-expected-for-immunogen-inc-imgn-this-quarter.html.

Several hedge funds and other institutional investors have recently modified their holdings of the stock. KBC Group NV raised its position in shares of ImmunoGen by 6.4% in the first quarter. KBC Group NV now owns 299,613 shares of the biotechnology company’s stock worth $1,160,000 after buying an additional 17,893 shares in the last quarter. JPMorgan Chase & Co. raised its stake in ImmunoGen by 37,346.0% in the first quarter. JPMorgan Chase & Co. now owns 187,230 shares of the biotechnology company’s stock worth $725,000 after buying an additional 186,730 shares during the period. Envestnet Asset Management Inc. raised its stake in ImmunoGen by 2.8% in the first quarter. Envestnet Asset Management Inc. now owns 27,761 shares of the biotechnology company’s stock worth $107,000 after buying an additional 743 shares during the period. Parametric Portfolio Associates LLC raised its stake in ImmunoGen by 7.7% in the first quarter. Parametric Portfolio Associates LLC now owns 38,492 shares of the biotechnology company’s stock worth $149,000 after buying an additional 2,753 shares during the period. Finally, Ameriprise Financial Inc. acquired a new stake in ImmunoGen during the first quarter worth about $1,528,000. 84.64% of the stock is currently owned by institutional investors and hedge funds.

ImmunoGen (NASDAQ IMGN) traded down 1.30% during midday trading on Thursday, reaching $8.36. The company’s stock had a trading volume of 6,817,307 shares. ImmunoGen has a 1-year low of $1.51 and a 1-year high of $8.84. The company’s market capitalization is $749.03 million. The company’s 50-day moving average price is $6.29 and its 200-day moving average price is $4.84.

ImmunoGen Company Profile

ImmunoGen, Inc is a clinical-stage biotechnology company that develops targeted cancer therapeutics using its antibody-drug conjugate (ADC) technology. The Company is engaged in the discovery of monoclonal antibody-based anticancer therapeutics. An ADC with the Company’s technology comprises an antibody that binds to a target found on tumor cells conjugated to one of its anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target.

Get a free copy of the Zacks research report on ImmunoGen (IMGN)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for ImmunoGen (NASDAQ:IMGN)

Receive News & Ratings for ImmunoGen Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmunoGen Inc. and related companies with MarketBeat.com's FREE daily email newsletter.